NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).
Medlab has received formal approval from the appropriate authority to proceed to stage II of the human cancer trial.
Stage II of the clinical trial will focus on further safety but also tolerance and dose escalation.
Key data findings from stage I include that NanaBis™ is safe, is effective up to nine hours in a single dose, and early indications confirm it helps with pain reduction.
Medlab’s CEO Dr Sean Hall said: “These results confirm and validate our original hypothesis and offer a true alternative to current pain medications.
“I’m looking forward to data from stage II.
“Although pain measurement was not a key part of stage I, the early results of pain reduction while being administered NanaBis™ was very encouraging.”
In stage II, Medlab will continue with cancer patients but this time with unmanaged pain.
In September, Medlab received preliminary results from research reviewing its patented delivery platform, NanoCelle™.
NanoCelle™ delivers medicine in a tiny particle form in a spray into the mouth and it is being tested using Medlab’s cannabis-based medicines, NanaBis™ and NanaBidial™.
The research concluded positively that molecules of the medicines, NanaBis™ and NanaBidial™ showed a consistent uniform pattern in nanoparticle form.
The type of work is critical as Medlab furthers its research endeavours for accepted, approved pharmaceuticals.